U.S. COMPANY FILING
Edwards Lifesciences Corp — Form 10-Q filed 2025-11-05
Filing text preview
Edwards Lifesciences reported Q3 2025 net sales of $1,553.1M, up 14.7% YoY, but continuing ops net income fell 19.3% to $292.3M. The company faces FTC opposition to its JenaValve acquisition, recorded $40M intangible asset impairment and $47.1M option impairment, and continues share repurchases. Court decision on JenaValve expected by Q1 2026.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record